Logo image of MDXG

MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis

NASDAQ:MDXG - Nasdaq - US6024961012 - Common Stock - Currency: USD

6.48  +0.09 (+1.41%)

After market: 6.48 0 (0%)

Fundamental Rating

5

Overall MDXG gets a fundamental rating of 5 out of 10. We evaluated MDXG against 558 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year MDXG was profitable.
MDXG had a positive operating cash flow in the past year.
In multiple years MDXG reported negative net income over the last 5 years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
MDXG Yearly Net Income VS EBIT VS OCF VS FCFMDXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

MDXG's Return On Assets of 14.86% is amongst the best of the industry. MDXG outperforms 96.06% of its industry peers.
The Return On Equity of MDXG (19.82%) is better than 96.24% of its industry peers.
MDXG's Return On Invested Capital of 14.58% is amongst the best of the industry. MDXG outperforms 96.42% of its industry peers.
Industry RankSector Rank
ROA 14.86%
ROE 19.82%
ROIC 14.58%
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
MDXG Yearly ROA, ROE, ROICMDXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

With an excellent Profit Margin value of 11.40%, MDXG belongs to the best of the industry, outperforming 93.37% of the companies in the same industry.
The Operating Margin of MDXG (12.86%) is better than 94.09% of its industry peers.
In the last couple of years the Operating Margin of MDXG has remained more or less at the same level.
MDXG has a better Gross Margin (81.94%) than 86.02% of its industry peers.
MDXG's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.86%
PM (TTM) 11.4%
GM 81.94%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
MDXG Yearly Profit, Operating, Gross MarginsMDXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDXG is creating some value.
Compared to 1 year ago, MDXG has more shares outstanding
MDXG has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MDXG has an improved debt to assets ratio.
MDXG Yearly Shares OutstandingMDXG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
MDXG Yearly Total Debt VS Total AssetsMDXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

MDXG has an Altman-Z score of 10.61. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
MDXG has a Altman-Z score of 10.61. This is amongst the best in the industry. MDXG outperforms 87.81% of its industry peers.
The Debt to FCF ratio of MDXG is 0.29, which is an excellent value as it means it would take MDXG, only 0.29 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MDXG (0.29) is better than 96.06% of its industry peers.
MDXG has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
MDXG has a worse Debt to Equity ratio (0.09) than 64.52% of its industry peers.
Even though the debt/equity ratio score it not favorable for MDXG, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.29
Altman-Z 10.61
ROIC/WACC1.53
WACC9.53%
MDXG Yearly LT Debt VS Equity VS FCFMDXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 4.70 indicates that MDXG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.70, MDXG is in line with its industry, outperforming 50.54% of the companies in the same industry.
A Quick Ratio of 4.13 indicates that MDXG has no problem at all paying its short term obligations.
MDXG has a Quick ratio of 4.13. This is comparable to the rest of the industry: MDXG outperforms 48.03% of its industry peers.
Industry RankSector Rank
Current Ratio 4.7
Quick Ratio 4.13
MDXG Yearly Current Assets VS Current LiabilitesMDXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

MDXG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.78%.
MDXG shows a small growth in Revenue. In the last year, the Revenue has grown by 5.34%.
MDXG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.11% yearly.
EPS 1Y (TTM)-37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)5.34%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%4.13%

3.2 Future

Based on estimates for the next years, MDXG will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.19% on average per year.
MDXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.54% yearly.
EPS Next Y-13.48%
EPS Next 2Y10%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue Next Year8.4%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDXG Yearly Revenue VS EstimatesMDXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
MDXG Yearly EPS VS EstimatesMDXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 23.14, MDXG is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 94.80% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.46, MDXG is valued at the same level.
Based on the Price/Forward Earnings ratio of 18.47, the valuation of MDXG can be described as rather expensive.
92.83% of the companies in the same industry are more expensive than MDXG, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.30, MDXG is valued at the same level.
Industry RankSector Rank
PE 23.14
Fwd PE 18.47
MDXG Price Earnings VS Forward Price EarningsMDXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 94.98% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 95.16% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.82
EV/EBITDA 16.16
MDXG Per share dataMDXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2

4.3 Compensation for Growth

The decent profitability rating of MDXG may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10%
EPS Next 3Y8.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDXG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIMEDX GROUP INC

NASDAQ:MDXG (6/3/2025, 8:00:00 PM)

After market: 6.48 0 (0%)

6.48

+0.09 (+1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners70.4%
Inst Owner Change6.71%
Ins Owners2.22%
Ins Owner Change1.11%
Market Cap957.10M
Analysts81.82
Price Target12.24 (88.89%)
Short Float %3.69%
Short Ratio7.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.48%
Min EPS beat(2)-31.92%
Max EPS beat(2)6.95%
EPS beat(4)3
Avg EPS beat(4)9.74%
Min EPS beat(4)-31.92%
Max EPS beat(4)52.51%
EPS beat(8)7
Avg EPS beat(8)71.29%
EPS beat(12)9
Avg EPS beat(12)45.41%
EPS beat(16)12
Avg EPS beat(16)48.58%
Revenue beat(2)2
Avg Revenue beat(2)1.09%
Min Revenue beat(2)0.32%
Max Revenue beat(2)1.86%
Revenue beat(4)2
Avg Revenue beat(4)-0.5%
Min Revenue beat(4)-3.85%
Max Revenue beat(4)1.86%
Revenue beat(8)6
Avg Revenue beat(8)1.5%
Revenue beat(12)8
Avg Revenue beat(12)1.63%
Revenue beat(16)12
Avg Revenue beat(16)2.9%
PT rev (1m)-11.11%
PT rev (3m)-7.69%
EPS NQ rev (1m)-13.6%
EPS NQ rev (3m)-30.32%
EPS NY rev (1m)-10.55%
EPS NY rev (3m)-20.65%
Revenue NQ rev (1m)-2.12%
Revenue NQ rev (3m)-2.94%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)-0.72%
Valuation
Industry RankSector Rank
PE 23.14
Fwd PE 18.47
P/S 2.72
P/FCF 14.82
P/OCF 14.61
P/B 4.72
P/tB 5.56
EV/EBITDA 16.16
EPS(TTM)0.28
EY4.32%
EPS(NY)0.35
Fwd EY5.41%
FCF(TTM)0.44
FCFY6.75%
OCF(TTM)0.44
OCFY6.85%
SpS2.39
BVpS1.37
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 14.86%
ROE 19.82%
ROCE 19.89%
ROIC 14.58%
ROICexc 27.36%
ROICexgc 36.54%
OM 12.86%
PM (TTM) 11.4%
GM 81.94%
FCFM 18.33%
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score5
Asset Turnover1.3
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.29
Debt/EBITDA 0.33
Cap/Depr 11.12%
Cap/Sales 0.27%
Interest Coverage 27.66
Cash Conversion 121.79%
Profit Quality 160.71%
Current Ratio 4.7
Quick Ratio 4.13
Altman-Z 10.61
F-Score5
WACC9.53%
ROIC/WACC1.53
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-13.48%
EPS Next 2Y10%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue 1Y (TTM)5.34%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%4.13%
Revenue Next Year8.4%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%
EBIT growth 1Y-18.47%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year25.32%
EBIT Next 3Y18.64%
EBIT Next 5YN/A
FCF growth 1Y533.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y659.04%
OCF growth 3YN/A
OCF growth 5YN/A